Femasys has announced a strategic partnership with Boston IVF to offer FemaSeed, its FDA-cleared intratubal insemination product, across Boston IVF’s network of nearly 30 fertility centers in the U.S. The collaboration aims to expand access to alternative fertility treatment options before patients progress to more invasive procedures.
“We are elated to welcome Boston IVF, a prominent conglomerate in the infertility space, to our growing group of providers offering our FemaSeed treatment to their patients looking for fertility solutions,” said Femasys CEO Kathy Lee-Sepsick. “Our partnership with Boston IVF exemplifies our shared commitment to the expansion of infertility treatment options with groundbreaking technologies for women and couples. FemaSeed’s accessibility as an efficacious alternative to intrauterine insemination (IUI) and prior to in vitro fertilization (IVF) stands to enhance practice economics while satisfying the needs of patients particularly at the beginning of their journey.”
The FemaSeed technology delivers sperm directly to the fallopian tube where conception naturally occurs. Clinical data has shown promising results, particularly for cases involving low male sperm count. The company reports that in their clinical trials, pregnancy rates were 26.3% by subject and 17.5% by cycle after FemaSeed treatment, compared to a 6.7% pregnancy rate by cycle described in literature for intrauterine insemination with male factor.
“As pioneers in reproductive healthcare and research, our team at Boston IVF is always looking for innovative technologies that expand choices and improve potential outcomes for our patients. We believe additional options are needed in infertility treatment and believe FemaSeed will be a valuable addition to our suite of patient options,” said David Stern, CEO of Boston IVF.
Dr. Jamil Mroueh, reproductive endocrinologist with Boston IVF, added: “I worked extensively with FemaSeed during our initial clinical evaluation and was consistently impressed with the ease of use and patient satisfaction to this new treatment. My patients expressed their excitement over FemaSeed as a new advancement and I believe we will be able to help more women now that we can provide this important treatment widely.”
The technology, which received FDA clearance in September 2023, has already secured regulatory approvals in Canada and Europe.
